Malaria Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Vaccine Type, By Route of Administration, By Region and Competition 2021-2031F

The Global Malaria Vaccine Market is projected to experience substantial growth, increasing from USD 1.41 Billion in 2025 to USD 3.84 Billion by 2031, achieving a CAGR of 18.17%. This sector focuses on the creation and distribution of biological preparations aimed at conferring acquired immunity against Plasmodium parasites. The primary forces driving this market are the critical imperative to reduce the disease burden in high-transmission areas and the strong procurement frameworks implemented by international health organizations. These structural pillars provide a consistent demand base independent of fleeting technological trends, ensuring that market expansion is rooted in enduring public health strategies rather than temporary research shifts.

Despite these positive indicators, the market confronts a significant hurdle regarding the disparity between manufacturing capacities and the immense scale of global demand, as supply chain constraints frequently impede the timely delivery of vaccines to remote regions. Data from Gavi, the Vaccine Alliance, indicates that in 2024, over 10.5 million malaria vaccine doses were procured and distributed to 17 endemic nations. This figure highlights the intense logistical pressures and the urgent need for expanded production facilities to adequately serve the requirements of the current market landscape.

Market Driver

The incorporation of malaria vaccines into National Routine Immunization Schedules serves as the primary engine for market growth, transitioning the sector from restricted pilot schemes to broad national adoption. This shift vastly expands the addressable patient population, requiring resilient supply chains and steadfast government dedication to consistent delivery. As noted in Gavi's April 2025 report, 'Rolling out vaccines to beat malaria together,' funding was approved for 25 countries to introduce the vaccine, signaling a rapid surge in demand beyond the initial pilot nations. To support this broad rollout, procurement agencies are actively negotiating beneficial commercial terms to maximize reach within budgetary limits, with UNICEF announcing in November 2025 that a new supply agreement secured US$ 90 million in savings to purchase millions of additional doses.

Furthermore, increased funding and procurement pledges from major international bodies provide the necessary financial stability for manufacturers to scale their operations. Distinct from private markets influenced by variable consumer spending power, this sector depends on sustained donor capital to reconcile the difference between production costs and affordability in low-income nations. These financial assurances enable pharmaceutical developers to invest in long-term capacity expansion without facing unmitigated market risks. For instance, Gavi announced in 2025 a plan to invest over US$ 1.1 billion in malaria vaccination programs during the 2026-2030 period, a commitment essential for aligning manufacturing output with global disease eradication goals.

Market Challenge

A critical constraint on the Global Malaria Vaccine Market is the disconnect between limited manufacturing capabilities and the immediate magnitude of global demand. Although international mandates drive substantial order volumes, the intricate biological processes required for production prevent manufacturers from rapidly increasing output to match this surge in interest. This imbalance creates a scenario where potential revenue is postponed, and the widespread adoption necessary for significant market valuation is physically restricted by product unavailability.

Consequently, supply chain bottlenecks and rigid production ceilings compel implementing organizations to ration distributions rather than fulfilling the total market potential. This inability to effectively service the total addressable market limits the industry's growth rate. According to UNICEF, the secured supply of the RTS,S vaccine in 2024 was restricted to approximately 18 million doses for the 2023-2025 period, a volume far below the immediate needs of eligible nations. Such constraints ensure that the actual market size remains smaller than demand models predict, with growth dictated more by logistical feasibility than by buyer intent.

Market Trends

The development of Next-Generation mRNA Vaccine Platforms marks a significant technological shift aimed at overcoming the efficacy limitations of earlier protein-based formulations. Developers are utilizing this scalable architecture to target multiple parasite stages, aiming to accelerate design iterations and enhance durability against the complex Plasmodium pathogen. However, the move to these novel mechanisms involves rigorous regulatory scrutiny typical for experimental biological platforms, which can lead to intermittent delays. For example, Contagion Live reported in March 2025 that the US FDA paused BioNTech's Phase I/II trial of the mRNA candidate BNT165e, which had enrolled nearly 180 participants, underscoring the strict safety protocols governing this technology.

Simultaneously, the localization of manufacturing capabilities in endemic regions is reshaping the global supply landscape by positioning production closer to high-burden populations. This structural trend seeks to reduce reliance on centralized intercontinental supply chains, thereby mitigating the logistical risks associated with importing finished doses. International health agencies are actively supporting regional autonomy by funding infrastructure that enables African nations to manage their own health security. As highlighted in an August 2025 World Health Organization report, Unitaid pledged nearly US$ 50 million to flagship programs designed to boost Africa's capacity to locally produce essential medical diagnostics and therapeutics.

Key Market Players

• GlaxoSmithKline, Plc.
• Novartis AG
• Takeda Pharmaceutical Company
• Sanaria Inc.
• Merck & Co.
• Johnson & Johnson
• Pfizer Inc.
• Serum Institute of India Private Limited
• Bharat Biotech International Limited
• Moderna Inc

Report Scope

In this report, the Global Malaria Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Malaria Vaccine Market, By Vaccine Type

• Pre-Erythrocytic
• Erythrocytic
• Multi-antigen
• Others

Malaria Vaccine Market, By Route of Administration

• Intramuscular
• Subcutaneous
• Intradermal
• Others

Malaria Vaccine Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Malaria Vaccine Market.

Available Customizations:

Global Malaria Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).